Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans

Cancer Biology and Therapy

Volumn 7, Issue 5, 2008, Pages 630-637

  Plastaras, John P ^a   Vapiwala, Neha ^a   Ahmed, Mona S ^a   Gudonis, Deborah ^a   Cerniglia, George J ^a   Feldman, Michael D ^a   Frank, Ian ^a   Gupta, Anjali K ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Akt; HIV; Ionizing radiation; Nelfinavir; Protease inhibitor; Radiation toxicity; Radiosensitization

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ATAZANAVIR; BIOLOGICAL MARKER; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NELFINAVIR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; RADIOSENSITIZING AGENT; TUMOR MARKER;

ACUTE TOXICITY; ANUS CARCINOMA; ARTICLE; BLADDER CARCINOMA; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KAPOSI SARCOMA; LUNG NON SMALL CELL CANCER; MALE; NONHODGKIN LYMPHOMA; OROPHARYNX CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE ADENOCARCINOMA; RADIOSENSITIVITY; RETROSPECTIVE STUDY; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING; ADULT; AGED; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; NEOPLASM; VIROLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NELFINAVIR; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION-SENSITIZING AGENTS; TUMOR MARKERS, BIOLOGICAL;

EID: 45349105168     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96:4240-5.
2. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
3. Grana TM, Rusyn EV, Zhou H, Sartor CI, Cox AD. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer research 2002; 62:4142-50.
4. Gupta AK, Bakanauskas VJ, Cerniglia GJ, Cheng Y, Bernhard EJ, Muschel RJ, McKenna WG. The Ras radiation resistance pathway. Cancer research 2001; 61:4278-82.
5. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ, McKenna WG. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. International journal of radiation oncology, biology, physics 2003; 56:846-53.
6. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS, Muschel RJ. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002; 8:885-92.
7. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9.
8. Bae SS, Cho H, Mu J, Birnbaum MJ. Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B. The Journal of biological chemistry 2003; 278:49530-6.
9. Cross DA, Watt PW, Shaw M, van der Kaay J, Downes CP, Holder JC, Cohen P. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. FEBS Lett 1997; 406:211-5.
10. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer research 2005; 65:8256-65.
11. Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 2007; 9:271-8.
12. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. The Journal of biological chemistry 2000; 275:8027-31.
13. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13:5183-94.
14. Kim IA, Bae SS, Fernandes A, Wu J, Muschel RJ, McKenna WG, Birnbaum MJ, Bernhard EJ. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer research 2005; 65:7902-10.
15. Jiang Z, Pore N, Cerniglia GJ, Mick R, Georgescu MM, Bernhard EJ, Hahn SM, Gupta AK, Maity A. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer research 2007; 67:4467-73.
16. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer research 2002; 62:5230-5.
17. Ikezoe T, Saito T, Bandobashi K, Yang Y, Koeffler HP, Taguchi H. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Molecular cancer therapeutics 2004; 3:473-9.
18. Pore N, Gupta AK, Cerniglia GJ, Jiang Z, Bernhard EJ, Evans SM, Koch CJ, Hahn SM, Maity A. Nelfinavir downregulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer research 2006; 66:9252-9.
19. Pore N, Gupta AK, Cerniglia GJ, Maity A. HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia 2006; 8:889-95.
20. Cuneo KC, Tu T, Geng L, Fu A, Hallahan DE, Willey CD. HIV protease inhibitors enhance the efficacy of irradiation. Cancer research 2007; 67:4886-93.
21. Bowers RK, Marder P, Green LJ, Horn CL, Faber AL, Thomas JE. A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy. Molecular cancer therapeutics 2007; 6:2600-7.
22. Di Paolo S, Teutonico A, Ranieri E, Gesualdo L, Schena PF. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am J Kidney Dis 2007; 49:462-70.
23. Chadha M, Rosenblatt EA, Malamud S, Pisch J, Berson A. Squamous-cell carcinoma of the anus in HIV-positive patients. Diseases of the colon and rectum 1994; 37:861-5.
24. Hocht S, Wiegel T, Kroesen AJ, Berdel WE, Runkel N, Hinkelbein W. Low acute toxicity of radiotherapy and radiochemotherapy in patients with cancer of the anal canal and HIV-infection. Acta oncologica (Stockholm, Sweden) 1997; 36:799-802.
25. Holland JM, Swift PS. Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology 1994; 193:251-4.
26. Gichangi P, Bwayo J, Estambale B, Rogo K, Njuguna E, Ojwang S, Temmerman M. HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer. Gynecologic oncology 2006; 100:405-11.
27. Kim JH, Sarani B, Orkin BA, Young HA, White J, Tannebaum I, Stein S, Bennett B. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Diseases of the colon and rectum 2001; 44:1496-502.
28. Hoffman R, Welton ML, Klencke B, Weinberg V, Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. International journal of radiation oncology, biology, physics 1999; 44:127-31.
29. Sparano JA, Wiernik PH, Hu X, Sarta C, Henry DH, Ratech H. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Medical oncology (Northwood, London, England) 1998; 15:50-7.
30. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clinical pharmacokinetics 2005; 44:111-45.
31. Blazy A, Hennequin C, Gornet JM, Furco A, Gerard L, Lemann M, Maylin C. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Diseases of the colon and rectum 2005; 48:1176-81.
32. Cleator S, Fife K, Nelson M, Gazzard B, Phillips R, Bower M. Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer 2000; 36:754-8.
33. Edelman S, Johnstone PA. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. International journal of radiation oncology, biology, physics 2006; 66:206-11.
34. Oehler-Janne C, Seifert B, Lutolf UM, Ciernik IF. Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. Radiation oncology (London, England) 2006; 1:29.
35. Place RJ, Gregorcyk SG, Huber PJ, Simmang CL. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Diseases of the colon and rectum 2001; 44:506-12.
36. Stadler RF, Gregorcyk SG, Euhus DM, Place RJ, Huber PJ, Simmang CL. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Diseases of the colon and rectum 2004; 47:1305-9.
37. Peiffert D, Giovannini M, Ducreux M, Michel P, Francois E, Lemanski C, Mirabel X, Cvitkovic F, Luporsi E, Conroy T, Gerard JP. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study. Ann Oncol 2001; 12:397-404.